



28<sup>th</sup> October 2024

The Secretary,  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001  
Scrip Code: 544250

The Secretary,  
The National Stock Exchange of India Limited  
C-1, Block G, Exchange Plaza  
Bandra-Kurla Complex  
Bandra East, Mumbai - 400 050  
Symbol: SANOFICNR

**Sub: Disclosure under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.**

Dear Sir/Ma'am,

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, please find attached the disclosure received from Sanofi regarding change in holding of Securities of Promoter of the Company. The Company received this disclosure from Sanofi on 25<sup>th</sup> October 2024 after close of Trading hours.

Kindly take the above information on record.

Thanking you,

Yours faithfully,  
For **Sanofi Consumer Healthcare India Limited**

---

**Nikunj Kumar Savaliya**  
**Company Secretary and Compliance Officer**  
**Membership No.: FCS 7048**

**Encl. a. a.**



Date: 25 October 2024

To,  
Sanofi Consumer Healthcare India Limited,  
3<sup>rd</sup> Floor,  
Sanofi House,  
CTS No. 117-B, L&T Business Park,  
Saki Vihar Road, Powai,  
Mumbai – 400072

**Re.: Disclosure under Regulation 7(2)(a) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“PIT Regulations”).**

We make reference to the prior intimation made by Opella Healthcare Participations BV (“**Opella**”) to the stock exchanges (namely BSE Limited and National Stock Exchange of India Limited) under Regulation 10(5) of the Takeover Regulations on 3 October 2024 informing about the proposed inter-se transfer of equity shares of Sanofi Consumer Healthcare India Limited (“**SCHIL**”), between Hoechst GmbH and Sanofi (then promoters of SCHIL, collectively the “**Sellers**”) and Opella (“**Acquirer**”/ “**Buyer**”) to be undertaken in one or more tranches.


The first tranche of the above-mentioned transaction was completed between Hoechst GmbH and Opella on 10 October 2024 wherein Hoechst GmbH transferred 1,39,04,722 equity shares of SCHIL (representing 60.37% of the equity share capital of SCHIL) to Opella.

We now wish to inform you that we, Sanofi, entered into a Share Transfer Agreement (“**STA**”) on 18 October 2024 with Opella for the inter-se transfer of the 4,865 equity shares of SCHIL (representing 0.02% of the equity share capital of SCHIL) held by Sanofi in SCHIL to Opella, and the same falls under the exemption from making an open offer as provided under Regulation 10(1)(a)(iii) of the Takeover Regulations. Pursuant to the STA, we, Sanofi, have sold our shareholding of 4,865 equity shares in SCHIL (which represented 0.02% of the equity share capital of SCHIL) to Opella on 25 October 2024.

Please find enclosed the disclosure in respect of the aforesaid sale.

# sanofi

For and on behalf of Sanofi



**Authorized Signatory**

**Name:** Carsten Vogel

**Designation:** Authorised Signatory

**Date:** 25 October 2024

**Place:** *Paris*



**SEBI (Prohibition of Insider Trading) Regulations, 2015**  
**[Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]**

Name of the company: Sanofi Consumer Healthcare India Limited (“SCHIL”)

ISIN of the company: INE0UOS01011

**Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).**

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter/member of the promoter group/designated person/Director/s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed				Securities held post acquisition/disposal		Date of allotment- <del>advice/</del> acquisition—of shares/disposal of shares, specify		Date of intimation to company	Mode of acquisition—/disposal (on-market/public/rights/preferential offer/off market/ Inter-se transfer, ESOPs, etc.)	Exchange on which the trade was executed
		Type of securities (For eg. – Shares, Warrant, Convertible Debentures, Rights entitlements etc.)	No. and % of share holding	Type of securities (For eg. – Shares, Warrant, Convertible Debentures, Rights entitlement, etc.)	No.	Value	Transaction Type (Purchase/sale Pledge / Revocation / Invocation/ Others-please specify)	Type of securities (For eg. – Shares, Warrant, Convertible Debentures, Rights entitlement, etc.)	No. and % of share holding	From	To			



1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
<b>Name:</b> Sanofi  <b>PAN:</b> AAICS4634D  <b>CIN:</b> <i>Not applicable</i>  <b>Address:</b> 46 Avenue de la Grande Armée, 75017 Paris, France  <b>Contact No.:</b> +33153774000	Promoter	Equity shares	4,865 (0.02%)	Equity shares	4,865 (0.02%)	23,263,700.25	Sale	Not Applicable (“N.A.”)	Nil	25 October 2024	25 October 2024	25 October 2024	Inter-se transfer of equity shares (undertaken off-market) which is exempt from making an open offer under Regulation 10(1)(a)(iii) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.	N.A.

**Note:** (i) “Securities” shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.  
(ii) Value of transaction excludes taxes/brokerage/any other charges



Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts *lot size)	Notional Value	Number of units (contracts *lot size)	
16	17	18	19	20	21	22
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

*Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.*



For and on behalf of Sanofi

---

**Authorised Signatory**

**Name:** Carsten Vogel

**Designation:** Authorised Signatory

**Date:** 25 October 2024

**Place:** Paris